This is the same criticism that caused the original sale of Connaught Labs (publicly owned vaccine developer). Market efficiency isn’t the goal; the ability to rapidly develop and distribute vaccines in an emergency is. The only problem is over-emphasizing Novavax as the sole manager/client of the new operation.

cbc.ca/news/politics/trudeau-m